Killer cell lectin-like receptor F1 (KLRF1) is an activating C-type lectin-like receptor expressed on human NK cells and subsets of T cells. In this study, we show that activation-induced C-type lectin (AICL) is a unique KLRF1 ligand expressed on tumor cell lines of hematopoietic and non-hematopoietic origins. We screened a panel of human tumor cell lines using the KLRF1 reporter cells and found that several tumor lines expressed KLRF1 ligands. We characterized a putative KLRF1 ligand expressed on the U937 cell line. The molecular mass for the deglycosylated ligand was 28 kDa under non-reducing condition and 17 kDa under reducing condition, suggesting that the KLRF1 ligand is a homodimer. By expression cloning from a U937 cDNA library, we identified AICL as a KLRF1 ligand. We generated mAbs against AICL to identify the KLRF1 ligands on non-hematopoietic tumor lines. The anti-AICL mAbs stained the tumor lines that express the KLRF1 ligands and importantly the interaction of KLRF1 with the KLRF1 ligand on non-hematopoietic tumors was completely blocked by the two anti-AICL mAbs. Moreover, NK cell degranulation triggered by AICL-expressing targets was partially inhibited by the anti-AICL mAb. Finally, we demonstrate that AICL is expressed in human primary liver cancers. These results suggest that AICL is expressed on tumor cells of non-hematopoietic origins and raise the possibility that AICL may contribute to NK cell surveillance of tumor cells.
Introduction
NK cells are innate immune lymphocytes that can eliminate certain tumor cells or virus-infected cells by their direct cytotoxicity (1, 2) . Activation of NK cells is determined by a balance of signals from various activating and inhibitory NK cell receptors, both of which consist mainly of either Ig-like receptors or C-type lectin-like receptors (3, 4) . The former group includes killer cell Ig-like receptors (KIRs) and natural cytotoxicity receptors, both of which are encoded in a chromosome region called the leukocyte receptor complex (5) (6) (7) (8) , while the latter group includes CD94/NKG2 family, NKG2D, NKR-P1, KLRG1 and killer cell lectin-like receptor F1 (KLRF1) (also called NKp80), which are encoded in a region called the NK gene complex (NKC) (9) (10) (11) .
Currently, two modes of target recognitions are known to enable NK cells to detect malignant self-cells. One is the 'missing self' recognition by inhibitory NK cell receptors for MHC class I, such as long-tailed KIRs, mouse inhibitory Ly49 receptors and human and mouse CD94/NKG2A (12) (13) (14) . The other is the 'induced self' detection by activating NK cell receptors for MHC class I-related molecules, such as NKG2D (15, 16) . However, MHC class I-specific receptors do not appear to be involved in all the NK cell activation processes (4, 17) . NK cell recognition of targets may involve orphan NK cell receptors, of which ligands are still unknown (11) .
KLRF1 was originally identified as a product of human cDNA that is homologous to human NKRP1A from an expressed sequence tag database (18) . Similar to other NKC-encoded molecules, KLRF1 is a type II transmembrane protein that has a C-type lectin-like domain (CTLD) on its extracellular region (18) . Though KLRF1 lacks typical activation motif and positively charged residues in the transmembrane region, mAb-mediated cross-linking of KLRF1 induces calcium mobilization and triggers NK cell cytotoxicity (19) . KLRF1 is conserved in several mammals including humans and non-human primates but absent in rodents (20, 21) . Importantly, KLRF1 is expressed on all NK cell populations and small subsets of T cells in humans (19) , but understanding of its functional role had been disturbed by the lack of information about KLRF1 ligand.
In this study, we identified a C-type lectin-like receptor AICL (activation-induced C-type lectin) (also called CLEC2B) as a KLRF1 ligand by using the expression cloning strategy. Although previous studies have suggested that AICL is expressed on hematopoietic cells including T cells, B cells and myeloids (22, 23) , we show the expression of AICL on non-hematopoietic cell lines and in human primary liver cancers. We also demonstrate that anti-AICL mAb partially inhibits NK cell degranulation triggered by AICLexpressing targets.
Methods

Cell lines and reagents
BWZ.36 cells were provided by N. Shastri (University of California Berkeley, Berkeley, CA, USA). 293T cells were purchased from Invitrogen (Carlsbad, CA, USA). BW5147, HEK-293, IMR32, AZ521, HL60, HUT78, K562, Raji, U937, A549, CoLoTC, HeLaS3, HepG2, ME180, SK-BR-3 and SK-MEL-28 cells were obtained from Cell Resource Center for Biomedical Research, Tohoku University (Miyagi, Japan). C32TG cells were obtained from American Type Culture Collection (Manassas, VA, USA). Mouse IL-6-transfected X63 cells and PAI cells were obtained from Dr H. Karasuyama (Tokyo Medical and Dental University, Tokyo, Japan). All the cell lines described above, except HEK-293, 293T, AZ521, HepG2 and PAI, were cultured in RPMI 1640 (Invitrogen) containing 10% heat-inactivated FCS (Invitrogen), 2 mM glutamine (Wako, Osaka, Japan), 50 lM 2-mercaptoethanol (Sigma, St Louis, MO, USA), 100 U ml À1 of penicillin G (Sigma) and 100 lg ml À1 of streptomycin (Sigma) (R10 medium). HEK-293, 293T, AZ521 and HepG2 were cultured in DMEM (Invitrogen) supplemented similarly as described for RPMI 1640 (D10 medium). PAI and established hybridomas were cultured in R10 medium containing 1 mM sodium pyruvate (Invitrogen), 13 non-essential amino acid (Sigma) and 50-100 U ml À1 of mouse IL-6 (culture supernatant of mouse IL-6-transfected X63 cells). The retroviral vectors, pMXs and pMXs-IRES-EGFP (pMXs-IG), and the retrovirus packaging cell line Plat-E (24) were provided by T. Kitamura (The University of Tokyo, Tokyo, Japan) and were used for retroviral transduction throughout this study. Plat-E cells were maintained in D10 medium containing 10 lg ml À1 of blasticidin S HCl (Invitrogen) and 1 lg ml À1 of puromycin (Sigma). All the cell lines were cultured at 37°C in 5% CO 2 .
Production of mAbs against KLRF1 and AICL Two 8-week-old female LEW/SsN Slc rats (Japan SLC, Shizuoka, Japan) were immunized with KLRF1-transfected 293T or AICL-transduced BW5147 cells. Lymph node cells from the rats were fused with PAI myeloma cells using Polyethylene Glycol 1500 (Roche Diagnostics GmbH, Mannheim, Germany). After the hypoxanthine-aminopterin-thymidine selection, the hybridoma supernatants were assayed for the capacity to bind KLRF1-transfected CHO cells or that to activate BWZ.AICL reporter cells. We established one anti-KLRF1 mAb, H206 (IgG1), and four anti-AICL mAbs, 1E51 (IgM), 3G72 (IgG2a), 4E57 (IgG2a) and 6H32 (IgM).
KLRF1 reporter assays
A KLRF1 chimeric cDNA encoding the ectodomain of KLRF1 (Ser63 through Tyr231), the transmembrane region of mouse Ly49A (Ser40 through Ile66) and the cytoplasmic region of the mouse CD3f (Arg52 through Arg164) was cloned into the bicistronic retrovirus vector pMXs-IG to construct the KLRF1rep-pMXs-IG. BWZ.36 cells were transduced with the KLRF1rep-pMXs-IG and the empty pMXs-IG vectors to establish the KLRF1 reporter cell line BWZ.KLRF1 and the control cell line BWZ.EGFP, respectively. The reporter cells were co-cultured with the indicated target cells for 16 h, and b-galactosidase activity was determined by colorimetric assay using chlorophenol red-b-D-galactopyranoside (Wako) as a substrate. When sensitivity of the putative KLRF1 ligand to trypsin was examined, U937 cells were incubated in the presence or the absence of 6200 U ml À1 of trypsin (Sigma) at 37°C for 15 min, then fixed with 4% paraformaldehyde (Wako) on ice for 15 min and then washed three times with PBS, before the co-incubation with the reporter cells.
In some experiments, the hybridoma supernatants containing anti-AICL mAbs were added into the culture. When the reporter cells were stimulated by antibody-mediated cross-linking, the reporter cells were cultured for 16 h on the ELISA plates (Greiner Bio-One, Frickenhausen, Germany) that were coated with 100 lg ml À1 of the indicated antibodies at 4°C overnight.
KLRF1-Fc fusion protein
A cDNA fragment encoding the extracellular region of human KLRF1 was fused to the 3# end of the Fc segment of the human IgG1 (provided by H. Arase, Osaka University, Osaka, Japan) as described in Fig. 2(A) , and the construct was cloned into the pRc/CMV vector (Invitrogen). HEK-293 cells were stably transfected with the KLRF1-Fc expression vector by Lipofectamine 2000 (Invitrogen) and were selected in the culture medium containing 1 mg ml À1 of G418 (Sigma). After cloning by limiting dilution, the clone with the highest production of KLRF1-Fc fusion protein was chosen and was subjected to large-scale cultures. KLRF1-Fc fusion protein was purified from the supernatants by affinity chromatography on a HiTrap rProtein A FF column (GE Healthcare, Piscataway, NJ, USA) using AKTA Explorer system (GE Healthcare).
Flow cytometry
Cells were stained with the appropriate mAbs and then with PE-goat anti-mouse IgG F(ab#) 2 fragment (Beckman Coulter, Fullerton, CA, USA), which is cross-reactive with rat antibodies. Alternatively, cells were stained with KLRF1-Fc fusion protein and then with PE-goat anti-human IgG F(ab#) 2 fragment (Jackson ImmunoResearch, West Grove, PA, USA). Data were acquired with a FACSCalibur system (BD Biosciences, Franklin Lakes, NJ, USA) and were analyzed with the FlowJo software (TreeStar, San Carlos, CA, USA).
Precipitation of a putative KLRF1 ligand
KLRF1 ligands were precipitated from the lysates of U937 cells that had been surface-biotinylated with Biotin-AC 5 Sulfo-OSu (Dojindo, Kumamoto, Japan) with the KLRF1-Fc fusion protein and rProtein A Sepharose 4 FF beads (GE Healthcare). The precipitates were treated with Nglycosidase F (Roche Diagnostics GmbH), separated by SDS-PAGE and transferred to polyvinylidene fluoride membrane (Immobilon-P; Millipore, Schwalbach, Germany). The biotinylated proteins were visualized by HRP-conjugated streptavidin (Pierce, Rockford, IL, USA) and ECL western blotting detection reagents (GE Healthcare).
Expression cloning
A U937 cDNA library containing 6.9 3 10 6 independent clones was constructed on the pMXs vector and used for transduction of BW5147 cells. The cells positive for the KLRF1-Fc fusion protein were enriched by four rounds of sorting with an EasySep PE Selection Kit (StemCell Technologies, Vancouver, Canada). Genomic DNA extracted from the enriched population was used as a template to amplify the cDNA inserts by PCR using primers specific for the pMXs vector. The amplified cDNA fragments were cloned into the pBluescript II SK (+) vector (Stratagene, La Jolla, CA, USA) and sequenced.
NK cell degranulation assays
To enrich NK cells, peripheral blood lymphocytes from a healthy donor were cultured with 5 3 10 5 cells ml À1 of RPMI 8866 cells that were irradiated with 50 Gy of c-ray in R10 medium containing 200 U ml À1 of recombinant human IL-2, a generous gift from Dr Suzuki (Ajinomoto Corporation, Tokyo, Japan). Seventy to 90% of the cells used for the NK cell degranulation assays were CD3 À , CD56 + NK cells, determined by FACS analysis. Almost all the NK cells expressed KLRF1. The CD107a degranulation assay was performed as described by Alter et al. (25) . In short, 5 3 10 4 of NK cells were co-cultured with 1 3 10 4 of the indicated target cells in U-shaped bottom 96-well plates in 100 ll of R10 medium containing 200 U ml À1 of human IL-2 and GolgiStop (BD Healthcare) in the presence of PE-Cy7-conjugated anti-human CD107a mAb (BD Healthcare) or PE-Cy7-conjugated control mAb (BD Healthcare). When indicated, the anti-AICL antibody 1E51 or the control antibody (anti-mouse KLRH1 antibody) was added. After 7 h of culture at 37°C, the cells were collected and stained with FITC-conjugated anti-human CD3 mAb (BD Healthcare) and PE-conjugated anti-human CD56 (BD Healthcare) and analyzed with FACSCalibur and FlowJo software.
Immunohistochemical staining
Liver specimens from patients with liver cancer were analyzed. Formalin-fixed specimens were embedded in paraffin and cut into 3-lm sections. Immunohistochemial staining procedures were performed in accordance with the ATLAS immunohistochemistry standard protocol. In brief, the sections were rehydrated and endogenous peroxidase was blocked by 0.3% H 2 O 2 in methanol. Antigen retrieval was performed by boiling the sections in citrate buffer (pH 6.0). After the antigen retrieval, the sections were stained with 0.8 lg ml À1 of rabbit anti-human CLEC2B polyclonal antibody (ATLAS, Stockholm, Sweden) at 4°C for overnight. Antibody binding was detected by using EnVision+ System-HRP Labeled Polymer Anti-Rabbit (Dako, Glostrup, Denmark) and peroxidase substrate 3,30-diaminobenzidine tablet (Dako). Sections were counterstained with hematoxylin and observed under a BX60 microscope equipped with a DP-70 digital camera system (Olympus, Tokyo, Japan).
Results
Expression of putative KLRF1 ligands on human cell lines
To identify the cell lines that express KLRF1 ligand(s), we generated the KLRF1 reporter cell line BWZ.KLRF1, which enabled us to detect binding of the KLRF1 ectodomain to the putative ligands. The BWZ.KLRF1 reporter cell line expressed the KLRF1 ectodomain on the cell surface (Fig. 1A) and produced b-galactosidase in response to the stimulation with immobilized anti-KLRF1 mAb (Fig. 1B) . Using the KLRF1 reporter cell line, we screened a panel of human cell lines from various origins. Six cell lines, including three leukemia lines (HUT78, K562 and U937), two carcinoma lines (HeLaS3 and ME180) and a melanoma line (C32TG), activated the KLRF1 reporter cells (Fig. 1C) . In particular, the monocytic leukemia line U937 induced the strongest activation. We also produced recombinant KLRF1-Fc fusion protein to detect the direct binding of the KLRF1 ectodomain to the cell lines. The KLRF1-Fc fusion protein, in which the extracellular region of KLRF1 corresponding to the CTLD and a part of the stalk domain was fused to the Fc region of human IgG1 ( Fig. 2A) , was expressed in HEK-293 cells (Fig. 2B) . The KLRF1-Fc fusion protein bound most intensely to U937 and weakly to K562, ME180 and C32TG, but did not bound to HL60, which did not stimulate the KLRF1 reporter cells (Fig. 2C) . The binding of KLRF1-Fc protein to the cells was completely inhibited by the anti-KLRF1 mAb, indicating that the binding is specific (Fig. 2D ). Among the cell lines that activated the KLRF1 reporters, we failed to detect the binding of the KLRF1-Fc protein to the HUT78 and HeLaS3 cell lines (Fig. 2C) , which might be due to the low level expression of the putative KLRF1 ligands on these cell lines. These results indicate that putative KLRF1 ligands are expressed widely among various cell lines, including leukemia, carcinoma and melanoma cell lines, and most abundantly in the U937 cell line.
Biochemical analysis of putative KLRF1 ligands
To characterize the putative KLRF1 ligands, we first examined the protease sensitivity of the ligands. When U937 cells were pre-treated with trypsin, the activation of the KLRF1 reporter cells was greatly diminished (Fig. 3A) , suggesting that the putative KLRF1 ligand(s) on U937 cells is a cell surface protein. To characterize the KLRF1 ligand protein, we next pulled down the putative ligands from the lysates of the cell Expression of AICL in tumor cells 785 surface-biotinylated U937 cells with the KLRF1-Fc protein and analyzed the precipitates before and after removal of N-glycan by endo-N-glycosidase F. When the precipitates were treated with endo-N-glycosidase F, a band with the apparent molecular mass of 28 kDa under non-reducing condition and 17 kDa under reducing condition were detected specifically in the KLRF1-Fc protein precipitates (Fig. 3B) , while the corresponding band was not detected when the precipitates were not treated with endo-N-glycosidase F. These results suggest that the putative KLRF1 ligand expressed on U937 is a homodimeric glycoprotein, of which protein core has an apparent molecular mass of 17 kDa, and that the N-glycan moiety of the KLRF1 ligand may have heterogeneities.
Identification of AICL as the KLRF1 ligand expressed on U937 cells
To identify the KLRF1 ligand expressed on U937 cells, we took an expression cloning strategy. We constructed a U937 cDNA retroviral library and transduced mouse thymoma BW5147 cells, which naturally do not bind the KLRF1-Fc fusion protein. The transduced cells were stained with the KLRF1-Fc fusion protein and then the population that bound the KLRF1-Fc fusion protein was enriched by magnetic separation. After four rounds of enrichment, we obtained a population that was >96% positive for KLRF1-Fc binding (Fig. 4A) . The retroviral inserts in the genome of the enriched population were PCR amplified, cloned and then sequenced. By sequencing 16 clones, we identified four different cDNAs encoding functional membrane proteins, one of which was AICL (also called CLEC2B), a C-type lectin-like molecule that is encoded in the proximity of the KLRF1 gene (20) . We transduced BW5147 cells with each of the four cDNAs and examined the capacity of the transduced cell lines to bind the KLRF1-Fc fusion protein and to stimulate the KLRF1 reporter cells. Of the four transduced cell lines, only AICL-transduced BW5147 cells bound the KLRF1-Fc fusion protein and stimulated the KLRF1 reporter cells (Fig. 4B  and C) . In agreement with the biochemical nature of the putative KLRF1 ligand on U937 cells, AICL is a glycoprotein with a molecular mass of 17 307 in the unglycosylated form (22) . These results indicate that AICL is a ligand for KLRF1. 
AICL is a unique KLRF1 ligand expressed on nonhematopoietic as well as hematopoietic cell lines
Despite the previous report that AICL is rather specifically expressed on hematopoietic cells (22, 23) , we found that non-hematopoietic cell lines, such as HeLaS3, ME180 and C32TG, also express KLRF1 ligands ( Figs 1C and 2C ). To ask if the KLRF1 ligands expressed on the non-hematopoietic cell lines are AICL, we generated four anti-AICL mAbs by immunizing rats with AICL-transduced BW5147 cells. All the four anti-AICL mAbs, 1E51, 3G72, 4E57 and 6H32, specifically bound to AICL-transduced BW5147 cells (Fig. 5A) . We also examined the capacity of the anti-AICL mAbs to block the KLRF1-AICL interaction. Of the four mAbs, the 1E51 and 6H32 mAbs completely inhibited KLRF1 reporter response to AICL-expressing BW5147 cell line (Fig. 5B ). Using these anti-AICL mAbs, we examined the expression of AICL on the tumor cell lines. The anti-AICL mAbs stained all the cell lines that activated the BWZ.KLRF1 reporter cells, including the non-hematopoietic cell lines HeLaS3, ME180 and C32TG (Fig. 6A) . To further exclude the possibility that KLRF1 ligands other than AICL are present on the nonhematopoietic cell lines, we examined the effect of the blocking anti-AICL mAbs on the KLRF1 reporter response to non-hematopoietic cell lines. The KLRF1 reporter response to the non-hematopoietic cell lines HeLaS3, ME180 and C32TG as well as to the hematopoietic cell lines K562, HUT78 and U937 was completely inhibited by either of the blocking mAbs against AICL, 1E51 and 6H32 (Fig. 6B , data not shown). These data indicate that AICL is a unique KLRF1 ligand expressed in non-hematopoietic cell lines as well as hematopoietic cell lines.
Blocking of AICL partially inhibits NK cell degranulation induced by AICL-expressing target cells
To examine the possible involvement of KLRF1-AICL interaction in the NK cell recognition of AICL-expressing target cells, we examined the effect of anti-AICL blocking mAb on the NK cell degranulation induced by AICL-expressing target cells. NK cells were co-cultured with AICL-positive (HeLaS3 and C32TG) or AICL-negative (HL60) target cells (Fig. 7A and B) . These data suggest that the interaction between KLRF1 and AICL contribute to NK cell recognition of target cells.
Expression of AICL in human liver cancer
Our above data demonstrate that AICL is expressed in nonhematopoietic as well as hematopoietic cell lines. To examine whether AICL is also expressed in human primary cancers, we performed immunohistochemical staining. Paraffin-embedded liver specimens from 20 cases of liver cancer were stained by anti-AICL polyclonal antibody. Among 20 cases examined, expression of AICL was observed in 12 cases, in which plasma membrane of cancer cells were stained (Fig. 8A-C) . These data suggest that AICL is expressed not only in established cell lines but also in primary human cancers.
Discussion
The target recognition mechanism of NK cells has been elucidated by studies on NK cell receptors (3, 4, 8) . It is previously shown that NK cells are armed with various receptors that recognize the self-MHC (-related) molecules to discriminate normal cells from malignant cells (13, 14) . On the other hand, the roles of NK cell receptors for non-MHC ligand have recently been revealed (26) (27) (28) . For example, the identification of E-, N-and R-cadherins as the KLRG1 ligands gave us an insight into the possible biological role of KLRG1 as a detector of invasive malignant cells (29) .
In this study, we show that KLRF1 ligand is expressed on several cell lines from various origins, including leukemia, carcinoma and melanoma, and identified AICL as the KLRF1 ligand. To identify the cell lines that express KLRF1 ligands, we screened human cell lines using the KLRF1 reporter cell line. The KLRF1 reporter cell line BWZ.KLRF1 was stimulated by three leukemia lines (HUT78, K562 and U937), two carcinoma lines (HeLaS3 and ME180) and a melanoma line (C32TG), indicating that these lines express KLRF1 ligand on the cell surface (Fig. 1C) . These cell lines, except HeLaS3 and HUT78, were also stained with the KLRF1-Fc fusion protein (Fig. 2C) . The failure to detect binding of KLRF1-Fc fusion protein to HeLaS3 and HUT78 cells might result from the lower sensitivity of the KLRF1-Fc fusion protein binding assays than that of the KLRF1 reporter assays. Indeed, we successfully detected expression of the KLRF1 ligand AICL on the HeLaS3 and HUT78 cell lines (Fig. 6) .
We cloned the KLRF1 ligand cDNA from U937 cDNA library and found that it encodes AICL, which is a type II membrane glycoprotein with the molecular mass of 17 307 in the unglycosylated form (22) , consistent with the observed apparent molecular mass of 17 kDa for the deglycosylated KLRF1 ligand precipitated from U937 cells. AICL has three potential N-glycosylation sites in the CTLD (22) , which is also consistent with our result that the KLRF1 ligands expressed in U937 cells were heterogeneously N-glycosylated. We also showed that the KLRF1 ligand is expressed as a homodimer that is covalently linked with disulfide bond. Since AICL has a unique cysteine residue (Cys8) in the N-terminal transmembrane region except those in the CTLD (22) , the latter of which are presumably involved in intramolecular disulfide linkages, it is likely that the Cys8 contributes to homodimer formation.
Previous studies showed that AICL is specifically expressed in cells of hematopoietic origin, especially in myeloid cells, including monocytes, macrophages and granulocytes (22, 23 ). In the current study, we detected the expression of KLRF1 ligands in cells of non-hematopoietic origins, including carcinomas and a melanoma. To examine whether the KLRF1 ligands on the non-hematopoietic cells are AICL, we newly generated mAbs against AICL and showed that AICL is expressed on HeLaS3, C32TG and HUT78 cells. Our results that masking AICL on these cell lines by the blocking anti-AICL mAbs completely inhibited the activation of KLRF1 reporter cells by these cell lines clearly show that AICL is a unique KLRF1 ligand expressed on these non-hematopoietic cell lines.
We found that AICL is also expressed in human primary liver cancers. Among 20 cases of liver cancer, in 12 cases anti-AICL antibody stained cancer cells. Similar result that 6 among 12 cases of liver cancer are AICL positive is registered on the human protein atlas database (http://www. proteinatlas.org/). The database also includes some cases of AICL-positive non-hematopoietic cancers such as melanoma, glioma and lung cancers. These data together with our current results suggest that AICL is expressed not only in the tumor cell lines of non-hematopoietic origin but also in a part of non-hematopoietic primary cancers.
Initial study on KLRF1 demonstrated that antibodymediated ligation of KLRF1 activates NK cells and induces antibody-redirected lysis of Fc receptor-positive targets, suggesting that KLRF1 functions as an activation receptor or a co-stimulation receptor (19) . We show here that blocking KLRF1-AICL interaction partially inhibits the degranulation of NK cells triggered by AICL-expressing non-hematopoietic cell lines (Fig. 7) . Together with the results that AICL is expressed on the tumor cells with non-hematopoietic origin, the expression of AICL on non-hematopoietic tumors may confer the tumor cells susceptibility to NK cell-mediated cytotoxicity. Recent finding that KLRF1 is expressed on a highly responsive effector memory CD8 + T cells and promote the responsiveness of the T cells toward AICL-expressing cells (30) further raises the possibility that AICL expression on tumor cells may enhance lysis of the tumor cells by the effector memory CD8 + T cells. From an analogy with the established role of NKG2D ligands in tumor surveillance that the NKG2D ligands induced by genotoxic stresses act as 'induced self' markers and contribute to elimination of tumor cells (31) , it will be interesting to ask in the future studies whether the expression of AICL on the non-hematopoietic tumors is acquired in association with tumor transformation. A recent study by Thomas et al. (32) revealed an immune evasion strategy of Kaposi's sarcoma-associated herpesvirus K5 to protect against NK cell cytotoxicity by down-regulating AICL and Expression of AICL in tumor cells 789 NKG2D ligands. This finding implies the importance of the KLRF1-AICL interaction in immune surveillance from the side of pathogen.
In summary, we demonstrate that AICL is expressed in hematopoietic and non-hematopoietic tumor lines and primary human liver cancers. We show that AICL is a unique ligand for KLRF1 expressed on hematopoietic and non-hematopoietic tumors. We also show that blocking AICL on AICL-expressing non-hematopoietic cell line partially inhibits NK cell degranulation. Our findings imply the possible role of the KLRF1-AICL system in immune surveillance for non-hematopoietic tumors, which should be addressed extensively in the future studies. 
